SAN DIEGO, July 01, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2025 on Thursday, July 31, 2025, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
Earnings webcast details:
| • | Location: | https://investor.resmed.com | |
| • | Date: | Thursday, July 31, 2025 | |
| • | Time: | 1:30 p.m. PDT / 4:30 p.m. EDT | |
| • | International: | London, Thursday, July 31, 2025, 9:30 p.m. BST Sydney, Friday, August 1, 2025, 6:30 a.m. AEST |
Please note, Resmed does not use outside phone lines to access the earnings call, the call is accessible via the above webcast link only.
A replay of the earnings webcast will be accessible on Resmed’s investor relations website and available approximately two hours after the webcast. In addition, a phone replay will be available approximately three hours after the webcast and will be accessible from July 31, 2025, until August 14, 2025, at:
| • | U.S.: +1 877.660.6853 | |
| • | International: +1 201.612.7415 | |
| • | Conference ID: 13754703 |
About Resmed
Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.
| For investors | For media |
| +1 858.836.5000 | +1 619.510.1281 |
| This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$256.59 |
| Daily Change: | 0.18 0.07 |
| Daily Volume: | 488,305 |
| Market Cap: | US$37.620B |
May 01, 2025 April 03, 2025 January 30, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
